Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 15 2025
0mins
Source: Newsfilter
Merger Announcement: Ikena Oncology, Inc. has announced a merger with Inmagene Biopharmaceuticals, with stockholders approving the merger and a 1-for-12 reverse stock split, which will reduce the number of outstanding shares significantly.
New Trading Name and Ticker: Post-merger, the combined company will be renamed ImageneBio, Inc. and will trade on Nasdaq under the ticker symbol "IMA," with trading expected to begin around the end of July 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
